CAR-T Cell Therapy Targets

Chimeric antigen receptor (CAR) T-cell therapy is a kind of cancer treatment that uses cells from your own immune system. Doctors take a type of white blood cell from your body and genetically change the cells in a lab so they can better find your cancer. Then millions of these target-seeking cells are put back into your body. CAR-T Cell Therapy Targets refer to targets involved in CAR-T cell therapy. More information about CAR-T Cell Therapy, you can click the following link: https://www.cusabio.com/car-t-cell-therapy.html.

CUSABIO has successfully developed over several active proteins, covering the hottest investigational CAR-T cell therapy targets. All of these proteins with high purity and high binding activity. Therefore, CAR-T cell therapy target proteins in CUSABIO are the first choice for your scientific research.

Regard reading: CAR-T Cell Therapy- An Useful Treatment To Cancer.

High Purity

The purity of Recombinant Human PDL1 (CSB-MP878942HU1) is >95% as determined by SDS-PAGE.

The purity of Recombinant Human CD22 (CSB-MP004900HU) is >94% as determined by SDS-PAGE.

Highly Identical Protein Sequences

Based on the SEQUEST from database of Mammalian Cell host and target protein, the LC-MS/MS Analysis result of CSB-MP007479HU could indicate that this peptide derived from Mammalian Cell-expressed Recombinant Human EGFR.

Multi-validated Activity

• Functional ELISA: Recombinant Human EGFR (CSB-MP007479HU)

CUSABIO: EC50=1.404-1.905 ng/ml

VS

XX company: EC50=1.720-2.184 ng/ml

• LSPR: Recombinant Human EGFR (CSB-MP007479HU)

CUSABIO: KD：1.66e-7 M

VS

XX company: 1.19e-8 M